Journal: BMC Cancer

Article Title: Nitric-Oxide Synthase trafficking inducer (NOSTRIN) is an emerging negative regulator of colon cancer progression

doi: 10.1186/s12885-022-09670-6

Figure Lengend Snippet: NOSTRIN-induced alteration of transcripts associated with epithelial mesenchymal transition in HCT116 cells

Article Snippet: Anti-SNAI2/SLUG (Cat no. 9585), anti-SMAD2 (Cat no. 5339), anti-STAT3 (Cat no. 4904), anti-Caldesmon-1/CALD1 (Cat no. 12503), anti-Jagged1/JAG1 (Cat no. 2620), anti-Moesin/MSN (Cat no. 3150), anti-Vimentin/VIM (Cat no. 5741), anti-Integrinα5/ITGα5 (Cat no. 4705), anti-E-cadherin/CDH1 (Cat no. 3195), anti-Integrin-linked protein kinase1/ILK1 (Cat no. 3856), anti-CD44 (Cat no. 5640), anti-EpCAM (Cat no. 36746), anti-CD133 (Cat no. 86781) and anti-GAPDH (Cat no. 2118) antibodies were purchased from Cell Signaling Technology, USA and was used at 1:1000 dilution.

Techniques: Binding Assay

Journal: Acta Neuropathologica

Article Title: Oligosarcomas, IDH-mutant are distinct and aggressive

doi: 10.1007/s00401-021-02395-z

Figure Lengend Snippet: Oligosarcomas have a highly distinct proteome with evidence for smooth muscle differentiation. a Volcano plot of significantly differentially regulated proteins between oligosaroma and conventional grade 3 oligodendroglioma. Using the 500 most variable proteins of the dataset for principal component analysis ( b ) and unsupervised hierarchical clustering ( c ) differentiates oligosarcomas from conventional grade 3 oligodendrogliomas. d Heatmap shows upregulation of (smooth) muscle specific proteins in oligosarcomas (left) and immunohistochemistry confirms expression of CALD1 and ACTA2 (SMA) in tumor cells of oligosarcoma (right). Scale bar is 200 µm

Article Snippet: Primary antibodies were diluted as follows: IDH1 R132H (1:2, clone H09 [ ]), NF1 (1:4, clone NFC [ ]), p53 (1:50, Novocastra, Leica, Wetzlar, Germany), SMA (1:500, Cell Marque, Sigma Aldrich, St. Louis, USA), H3K27me3 (1:25, monoclonal antibody, Cell signalling, Danvers, USA), YAP1 (1:100, Cell signalling), Caldesmon (CALD1) (1:100, clone E89, zytomed-systems, Berlin, Germany), GFAP (1:2000, clone GA5, Cell signalling, Danvers, USA), OLIG2 (1:50, clone ERP 2673, Abcam, Cambridge, UK).

Techniques: Immunohistochemistry, Expressing